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Chapter 1 Structure-assisted Drug Design
INTRODUCTION
As the understanding of biomolecular structure advances, the hope of
predicting accurate structure-activity relationships becomesmore tantalizing.
The paradigm of structural biology dictates that the structure ofa molecule
determines its function. At this time, however, the ability to successfully
predict a molecule's function solely from its structure is feeble. Nowhere else
will strengthening this ability to predict activity from structure havegreater
impact than on structure-based drug design. This thesis deals with two
specific examples of steps towards structure-based drug design. Chapter 2
presents the determination of the absolute configuration of hectochlorin,a
natural product, having potential therapeutic applications, for thepurpose of
simplifying its synthesis. Chapter 3 describes the results of attempts to
crystallize, and ultimately determine the structure of an RNA molecule
critical to the human immunodeficiency virus life cycle, which isa potential
drug target.
Only in recent history, have bridges begun to form between the
awareness of an active compound in a natural product, and the structural
rationale for its therapeutic effects. Many plant-based remedies have long
been used before the underlying science for its action was understood. Salicinfrom the willow tree, used as a mild analgesic, is justone example. The
compound was isolated in 1829, but not until 1899, was the acetate ester of
salicylic acid introduced by Bayer, as aspirin (1). Only much laterwas
aspirin's action as a cyclooxygenase inhibitor discovered.
Historically, a newly discovered active compound was optimized
through rational drug development. Classic rational drug development isan
iterative process that develops a lead compound into a drug candidate. In this
process, a compound with some desired activity is selected and a library of
derivatives is created. By screening a batch of derivatives for improved
activity, a new best candidate is selected and derivatized again. The aim of
this process is to enhance desired activities while reducing undesirable
properties. This process is tried and true, albeit slow. Typically, thousands of
compounds are created and rejected along the path that leads to approval fora
single drug; this process frequently takes over a decade.
Structure based drug design offers an alternative to the tedious
screening of large libraries of compounds, looking for the proverbial needle
in the haystack. Structure based drug design is the ambitious concept that the
structure of a target receptor contains all the information required to design
an ideal ligand for that receptor. This approach can potentially be applied to a
broad spectrum of diseases. A crystal structure offers detailed positions of
atoms that make up the receptor and the surrounding solvent. Detailed
knowledge of the receptor's structure can guide the design of complementary
ligands that optimize favorable contacts and eliminate sterically unfavorable3
geometries within a bound complex. Structure based design of ligands will
theoretically result in tighter ligand binding, as evident from lower
dissociation constants. A tight binding ligand translates to a lower dose foran
equivalent desired effect; lower dose would potentially reduce concentration
dependent side effects.
Using structure-assisted drug design, it is theoretically possible to make
modifications to a ligand that will not only augment binding activity, but also
enhance other properties of the compound. A pro-drug is a modification toa
therapeutic agent's structure that, in addition to masking activity until
unveiled by metabolism, can improve other properties of the drug. Thereare
many qualities of a ligand that are desirable to control, such as a its solubility,
cellular uptake, tissue selectivity and metabolism. It is possible, for example,
to exchange substituents that are inconsequential to binding activity for
functional groups that are platforms for pro-drug development.
A true success for structure-assisted drug design resulted from workon
human immunodeficiency virus protease (HIV PR). Structure-assisted drug
design lead to development of novel compounds such as DMP-450. DMP-450
isC2symmetric and is designed to complement theC2symmetry of the HIV
protease receptor. Additionally, a keto oxygen in DMP-450 is designed to
displace a structural water found in HIV PR. Both concepts, the symmetry
and the incorporation of the keto oxygen, were derived directly from analysis
of the receptor's three dimensional structure. This compound shows4
remarkable specificity to HIV PR, is a potent inhibitor, and is resistantto
protease degradation (2, 3).
Perhaps more importantly, analysis of the HIV PR structure and
libraries of small molecule structures facilitated the discovery ofnew lead
compounds through computational screening. Usingprograms to sift
through libraries of small molecules,and to study their ability to dock into
the invaginations of the receptor site of HIV PR, has produceda number of
new lead compounds. These new compounds are unrelated to first
generation peptide mimics. This provides novel frameworksupon which
new families of inhibitors can be designed. In many cases, new lead
compounds were determined with mere hours of computation. This ability
to extract novel lead compounds that are selective for a specific binding site is
a major achievement in structural biology (4, 5).
One example of where future structure-assisted drug designmay
facilitate the development of a natural product into a drug is psoralen,a DNA
photocrosslinking agent. The plant source of this compound, Psora lea
corylifolia, is described in antique remedies for vitiligoas early as 1500 BC.
Not until the 1940s did scientists isolate the active compounds,now known
as psoralens. The base structure of psoralen was later determined to be
tricyclic and planar (6, 7).
Psoralen accumulates in unhealthy skin cells and tissue with increased
vascular flow. In the 1970s psoralen was shown to non-specifically intercalate
into DNA duplexes. When irradiated with light of 320-400 nm, the psoralen1
intercalated between 1-A steps becomes covalently crosslinked to the thymine
residues (6, 7).
Current research is being directed to develop therapies for cancer and
skin disease utilizing psoralen's photocrosslinking properties. An immediate
obstacle for this strategy is that the wavelengths that promote crosslinking do
not penetrate tissues effectively (7). However, longer wavelength radiation
has better tissue penetration properties. To increase the effectiveness of the
therapy, the parent structure of psoralen may be modified with substituents
that extend conjugation and hyperconjugation. This approach may extend
the wavelength at which the pi system is excited.
Recently, the atomic resolution structure of a psoralen compound
cross-linked to DNA has been solved (Eichman et al., manuscript submitted).
This structure may hold keys to overcoming the deficiency of psoralen
photocrosslinking therapy. Substituent modifications to psoralen that extend
the wavelengths required for cross-linking, yet don't interfere with critical
elements of DNA binding, may result from analysis of this structure.
As biology is a chiral realm, any drug design strategy must be concerned
with stereochemical details. A complete stereochemical description of the
ligand is integral to predicting interactions with the receptor site. Potentially,
the mere presence of required functional groups on a ligand is the sole
requirement for activity. However, it is more likely that the configuration of
functional groups is equally important to forming a cognate to the receptor'sstructure. Therefore, enantiomeric relationships are an important feature of
a ligand's structure activity relationships.
Enantiomers of drugs can have unanticipated effects. For example,
(R)-11-hydroxy-1O-methylaporphine is a selective agonist of 5-
hydroxytryptamine receptor 1A (5-HT1A). In contrast, (S)-1 1-hydroxy-1 0-
methylaporphine is an antagonist for the same5-HT1Areceptor.
Furthermore, one enantiomer can be primarily responsible for undesirable
side effects in a racemic mixture. Thalidomide is an often cited example of
one enantiomer being primarily responsible for unwanted side effects.
Animal tests, utilizing SWS mice, show both enantiomers of thalidomide
possess hypnotic effects but the S enantiomorph is culpable for teratogenic
side effects (8).
One of the most powerful tools in structure-assisted drug design is x-
ray crystallography. X-ray crystallography is an excellent tool for describing
the structure of a receptor's binding site and a ligand's structure in great detail.
This technique provides a three dimensional electron density map of
molecules in a single crystal. Greater map resolution translates into higher
confidence in the exact position of the atoms in the molecule.
PROBLEM DEFINITION
The structure of ligand and receptor must be accurately defined for
structure-assisted drug design to be applicable. X-ray crystallography is apowerful technique that provides this information. The following chapters
describe two examples of crystallography in drug design. Chapter 2 details the
absolute structure, determined by single-crystal x-ray diffraction, of
hectochiorin, a ligand with multiple stereocenters, and discusses possible
biogenesis pathways for the compound. Chapter 3 focuses on attempts to
crystallize a biologically important RNA structure, the trans-acting response
element, (TAR), for the determination of its structure by x-ray diffraction,
and, thus, provide a starting point for structure based drug design to target the
AIDS virus.Chapter 2 The Absolute Structure of Hectochiorin
INTRODUCTION
Hectochiorin, 1, is a cytotoxic secondary metabolite isolated from
Lyngbya majuscula that contains four stereogenic carbons. A secondary
metabolite is a molecule that may not be required for an organism to grow
and reproduce, but potentially confers some advantage for survival (9). In
the case of secondary metabolite-rich organisms such as terrestrial plants,
bacteria, and marine algae, the secondary metabolites may act as a deterrent to
predators or competitors. Interestingly, these metabolites can be useful in the
treatment of human disease or may have industrial applications. Therefore,
they are fervently investigated. Figure 2.1 shows the structure of four
secondary metabolites with medicinal or industrial applications, as classified
by their biosynthetic pathway.
Marine organisms are a rich source of novel compounds with potential
value. Curacin A is an example of a marine natural product with cancer
fighting properties. The molecule is isolated from a Lyngbya majuscula
harvested from the coastal waters of Curacao. This compound is a potent
inhibitor of microtubule formation, with anIC50value in the nanomolar
range. Furthermore, the compound demonstrates selective activity against
breast, colon, and renal cancer cell lines (10).Gramicidin S
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Figure 2.1 Secondary metabolites classed by their biosynthetic pathways. This
figure shows the structures of compounds representative of several classes of
biosynthesis: alkaloids, terpenes, polyketides, and non-ribosomal
polypeptides. Each has medicinal or industrial applications. Chrysanthemic
acid is a terpenoid moiety of an insecticide, erythromycin A is an antibiotic
polyketide, Gramicidin S is a non-ribosomal polypeptide antibiotic10
As further examples of marine natural products, consider cis, cis-, and
trans, trans-ceratospongamide. These compounds are isolated from
Ceratodictyonspongiosum/sigmadocia symbiotica, a red alga andsponge
symbiont. Trans. trans-ceratospongamide is an anti-inflammatoryresponse
agent. Secreted phospholipase (sPLA2) catalyzes the release of arachidonic
acid from membrane glycophospholipids. Arachidonic acid is modified into
eicosanoids that elicit an inflammation response. Trans. trans-
ceratospongamide is shown to effectively inhibit the expression ofsPLA2with
anED50of 32 nM. Thus, it limits the amount of arachidonic acid available for
eicosanoid synthesis and reduces the inflammation response. The cis, cis-
ceratospongamide isomer, however, is inactive in this assay. This
demonstrates that subtle aspects of structure are critical to the activity ofa
compound (11).
Hectochiorin, isolated fromLyngbyamajuscula, showed cytotoxicity in
brine shrimp, and snail assays. Additionally, a fungal assay withCandida
albicansshowed a 10.5 mm zone of inhibition at 10 .tg/mL. This activity
encourages further analysis and structure determination. Prior investigation
of 1 using NMR and MS revealed the molecular formula and the relative
structure containing four stereocenters. The four stereogenic carbons lead toa
total of sixteen possible stereoisomers. To completely characterize 1, the
absolute stereochemistry has to be unambiguously defined.
In this study, x-ray crystallography, incorporating anomalous scattering
data, was used to resolve the enantiomorph ambiguity. 1 contains two11
chlorine and two sulfur atoms which contribute sufficient anomalous
scattering, relative to the remaining scattering mass, to determine the
absolute configuration of the molecule. The compound readily provided
single crystals for absolute structure determination using x-ray
crystallography. Each stereocenter is clearly defined from the single crystal
study, thus completing characterization of the compound's absolute
stereochemical structure.
Given that 1 readily generates large diffraction quality crystals, x-ray
diffraction is an ideal tool for confirming relative stereochemistry. The heavy
atoms, sulfur and chlorine, provide the important advantage of anomalous
scattering for absolute stereochemistry determination. Because the number of
atoms in 1 is small, direct methods were used to solve the phase problem in
this experiment. The purpose of this chapter is to describe this work and the
resulting absolute structure of hectochlorin.
METHODS AND MATERIALS
Hectochiorin formed colorless crystals from equal parts of water and
methanol. A 0.3 x 0.3 x 0.3mm3crystal was mounted in a glass capillary tube.
Graphite monochromated Cu K radiation from a Siemens P4 sealed tube
source was used to record 5813 reflections representing data out to 0.85A
resolution. XSCANS (Siemens) employed 97 reflections stronger than 25to12
index the unit cell as P212121. The space group was confirmed by examination
of systematic reflection absences along Miller indices.
In an x-ray diffraction experiment the intensities of x-rays diffracted
from a single crystal are carefully measured. The dimensions andspace group
symmetry of the crystal's unit cell define the diffraction pattern, a
constellation of so-called "reflections". The individual reflections in the
pattern contain information about the contents of the unit cell.
Unfortunately, the measured reflection intensities alone do not afford the
relative positions of the atoms in the unit cell.
The complete structure factor, F(S), for each reflection contains
information on the scattering mass, f, and relative positions of each atom ina
unit cell (Eq 1). In Equation 1, S'r is the phase angle contribution to a single
reflection from a single atom, with r as the vector describing the atomic
position of the
.thatom.
F(h, k, 1)= F(S) = f exp 2i(S.r)Eq (1)
A three dimensional map of the electron density is generated bya summation
of the structure factors, as in Equation (2).
p(r) = (1 /V) F(h, k, 1) exp -2ti(S.r)Eq (2)
h=_ook=_oo l=_oo
To generate a correct and interpretable map of the unit cell, the phase angle of
each reflection must also be defined. The intensity, but not the phase, of each13
reflection is measured in a single experiment. Therefore, the phasemust be
determined separately. This is known as the phase problem in X-ray
crystallography (12).
Direct methods are a strictly mathematical approach to solving the
phase problem for a structure with a small number of atoms. Direct methods
result in an initial description of the electron densitymap, and hence,
approximate atomic positions. Three phases of normalized structure factors
from centric reflections, reflections that may adopt only two possible phases,
are arbitrarily defined to select an origin and coordinate system. Sets of
related normalized structure factors are chosen to estimate initial phases
using the triplet relationship, Equation (3)(13).
0t(h1,k1, l) + J(h2, k2, 12) + 'T(-(h1, k1, li,) + (h2, k2,12,)) Eq (3)
Starting from defined phases used to fix the origin and expanding the number
of estimated phases from the triplet relationship, the entire set of reflections
is phased sufficiently well to provide a first estimate densitymap. SHELXS is
a direct methods program for solving the phase problem for small molecules
(14). The output from SHELXS is a list of electron density peak positions
derived from these triplet relationships. A model is generated by assigning
the peaks in the initial map to atoms in the structure using chemical
intuition and all available information. For example, the highest electron
density peaks are designated as atoms with the most electrons in the chemical
formula.14
The initial model from direct methods is subsequently improved using
a least-squares matrix refinement. The square of the disagreement between
F(h, k,l)obsand F(h, k,l)caicis minimized by altering F(h, k, l)caic. F(h, k,l)caic
is composed of a number of modeled parameters. For example, thex, y, and z
position of all the atoms and the individual B-factors are constituent
variables of F(h, k,l)caic.The individual parameters are shifted slightly and
the value of the disagreement between F(h, k,l)obsand F(h, k,Dcaicis
evaluated. When the value of each parameter in F(h, k,l)caicis slightly
shifted yet the disagreement function remains at a minimum, parametersare
presumed refined. SHELXL used to refine the atomic positions and B-factors
inamodel (14).
Even the correct assignment of the phase magnitudes in a refined
model does not provide absolute stereochemistry by itself. The sign of the
phase angles determines the "handedness" of the electron densitymap. The
relative stereochemistry is all that could be gleaned from an x-ray diffraction
experiment without measurable anomalous scattering as described below
(15).
With the correct magnitude of the phase angle applied to the structure
factor of each reflection, the resulting map shows an accurate distribution of
electron density. However, a change in sign to each phase angle will generate
an equally accurate electron density map of the mirror image of the contents
of the unit cell. Determining the "handedness" of the map is an important15
consideration. For many systems, where stereochemistryis selected by nature
and known, the map "handedness"must agree with the natural
stereoisomer. Thus, in order to accept the signs of thephases, an electron
density map of a ribosomal product proteinmust show right-handed a-
helices with L-amino acids, anda map of a biosynthesized DNA must show
D-ribose sugars. In the case ofa newly discovered natural product, however,
the stereochemistry may not be prescribed. Manynatural products have D-
amino acids and incorporate a variety of other chiralmoieties that require
definition. Anomalous scattering data allows directdetermination of the
correct configuration of a natural product by X-ray crystallography.
The lengths and angles of the unit cell, with the righthand rule, define
the assignment of the Miller indices to all reflections.In a theoretical array of
scattering atoms, Friedel's law states that the phase anglefor a reflection with
Miller indices (h, k, 1) will have thesame magnitude but opposite sign as the
reflection with Miller indices (-h, -k, -1). The resultantbeam scattering from a
theoretical free electron, is 180 degrees out of phase fromthe incident beam
(12, 13).
In contrast, the electrons in real systemsare associated with atoms in
quantized levels. Interactions between incidentx-rays and electrons in real
systems, such as absorption or fluorescence, can result in small changes in the
magnitude and phase of the resultant structure factors. A breakdown of
Friedel's law results from these small changes. The effect ofanomalous
scattering on the magnitude and phase of pair of structure factorsis shown in16
Figure 2.2. Anomalous scattering allows the determination of the correct
enantiomorph by comparing the structure factors observed fora Friedel pair
with the calculated structure factors for a particular enantiomer model (12,
13).
The program SHELXL can clearly distinguish between enantiomers
using anomalous scattering data. The enantiomer of the model is generated,
and the program queries how much of each enantiomer must be present to
account for observed data. If this value converges near 1.0 or 0.0 then the
crystal is enantiomerically pure. A returned value of 0.0 indicates data best
fits the original enantiomer model. A value of 1.0 suggests the mirror image
is best represented by the data. In this manner the absolute structure is clearly
determined (14).
The structure of hectochlorin was solved and refined with SHELXS and
SHELXL, respectively (14). A single hectochlorin molecule and one solvent
molecule constituted the asymmetric unit (ASU) of the crystal.
RESULTS AND DISCUSSION
The purpose of this study was to reveal the absolute structure of 1. 6S,
7S, lOS, 31S defines the stereochemistry. The data collection and refinement
statistics for hectochlorin are given in Table 2.1, the absolute structure is
shown in Figure 2.3, and an ORTEP representation of the ASU is shown in
Figure 2.4. The complete description of a molecular structure must includeA 1mg.
:,l)
teal
i,-k,-l)
B 1mg.
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Figure 2.2 The effect of anomalous scattering on Friedel mates. Panel A isan
Argand diagram of a structure factor F(h, k, I) and its Friedel mate F(-h,-k,-l)
without anomalous scattering. The vertical axis is the imaginary component
and the horizontal axis is the real component of the structure factor. The
angle from the positive real axis to the structure factor, F(h,k,l), is the phase
angle, From A, it is clear that Friedel's law is obeyed, and the magnitude
of the structure factor intensities and phases are identical; only the sign of the
phase is different. In panel B, the same structure factorsare presented with
anomalous scattering, where Friedel's law no longer holds true. The
anomalous intensity magnitude is represented by the vector f'. The
anomalous change in phase angle is represented by the vector f". The
resultant structure factors F'(h, k, 1) and F'(-h,-k,-l)are therefore
distinguishable by intensity magnitude and phase angle (12, 13).18
Table 2.1 Data collection and refinement statistics for hectochlorin. Space
group and unit cell dimensions are reported along with refinement statistics.
Definitions of refinement values are included below table.
Space Group P212121
Unit Cell
a, A 12.266
b,A 12.684
c,A 21.415
degrees 90
Refinement
parameters*
R 6.66 % (5.59 %)
wR2 15.33 % (14.33 %)
GooF for 407 parameters 1.043
*The R and wR2 values in parenthesisare for reflections withF2> 4 c, the
refinement parameters are defined below.
R I I(Fobs)I I(Fcaic)I I/ ZIFObSI
2 2 22 221/2 wR ={(w(F0b5 Fcaic )) /(w(FobS ))}
GooF (Goodness of Fit)S = { (w(F0b52Fcaic2)
2)/ (n
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Figure 2.3 The absolute structure of hectochlorin. The single crystalstructure
of hectochlorin agrees with the structure determined from NMR and MS
data. Structural features of note include four ester linkages,a saturated
chlorinated carbon chain, and two thiazole rings. The numbering schemeis
arbitrary.20
Figure 2.4 ORTEP representation of the non-hydrogen atoms of hectochiorin.
The absolute structure is defined by x-ray crystallography and anomalous
scattering data. Ellipses are drawn at 50 % probability. The detailed structure
shows the stretching, rocking, and scissoring of bonds in the molecule.21
the stereochemistry. Furthermore, to further study the value of 1as a
therapeutic agent or its industrial applications, large amounts of materialare
required. With the absolute configuration now defined, development of
large scale synthesis and derivatization of the correct stereoisomercan now
proceed.
The refined single crystal structure confirms the structure obtained
earlier from NMR and MS data. The atoms in the hectochiorin crystal
structure agree with the molecular formula, C27H34N209S2C12. The molecule
contains two thiazole rings, four carbonyls, two carbons with geminal
methyls, and a saturated carbon chain with geminal chlorine substituents.
Additionally, a hydrogen bound solvent molecule is clearly evident in the
crystal structure.
The crystal structure shows three ester linkages and two thiazole rings
form a large ring of hydrogen bonding contacts to the solvent molecule. A
single solvent molecule is encompassed by both imino nitrogens in the
thiazole rings, and the hydroxyl group from a symmetry related molecule,
which indicates the solvent molecule is constrained in the crystal by at least
three hydrogen bonds. The N19 to solvent oxygen distance is 2.97A,the N26
to solvent oxygen distance is 2.80A,and the distance between the solvent
oxygen and symmetry related 014 is 2.65A.The angle formed by N19,
solvent oxygen, and N26 is 95.96°. The angle between N19, solvent oxygen,
and symmetry related 014, is 110.78°. The N26, solvent oxygen, symmetry
related 014 angle is 116.48°. Additionally, three ester oxygens are 3.08A,3.1922
A,and 3.23Aaway from the solvent molecule. Small deformation of the
structure may reduce these distances and present a second perimeter of
hydrogen bond contacts. Hydrogen bonds effectively ensnare the solvent
molecule within the macrocyclic ring.
The gross structure of 1 is similar to dolabellin 2, shown in Figure 2.5.
2 is isolated from the sea hareDolabella auricularia, and exhibits cytotoxic
activity againstHeLa-S3cells (16). 2 also has four stereocenters, with two
centers differing in absolute stereochemistry from 1. Differing biogenesis
pathways may explain why the stereochemistry at C31 of 1 differs from the
stereochemistry at the analogous stereocenter in 2. That is, a different
stereogenic precursor is selected in the biosynthesis of each molecule; glyceric
acid is probably condensed into a thiazole ring in 2, where
cx,f3dihydroxyisovalerate or dimethylallyl diphosphate is likely the precursor
condensed in 1 to form a similar ring. The other stereocenter in 2 that differs
from the analogous stereocenter in 1 is at C7. In 2, the stereocenter in
question was defined by synthesis of two possible fatty acid fragment isomers
under stereoselective conditions. The isomers were characterized by optical
rotation and NMR. The assignment was based on comparison of synthetic R,
S and synthetic R, R to the relevant degradation product of 2. Presuming no
error in assignment from the optical data, the biosynthesis pathways must be
different.
To further discuss the structural details and possible biogenesis
pathways, consider the theoretical hydrolysis fragments of hydrolysis of the1
HOfi/
23
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Figure 2.5 Structure comparison between hectochiorin, 1, and dolabellin, 2.
Hectochiorin 1 is isolated from Lyngbya majuscula. 2 is isolated from the sea
hare Dolabella auricularia. Inspection reveals a similarity between the gross
structure of the two compounds. Furthermore, each compound has four
stereogenic carbons.24
esters would result in the fragments represented in Figure 2.6. The imaginary
hydrolysis would yield two equivalents of fragment A, which contains a
thiazole ring, the predominant chromophore in 1. The biogenesis of this
fragment can be hypothesized to proceed by at least two routes. One
possibility is the condensation a cysteine amino acid to a dimethylallyl
diphosphate. The dissociation of thePP1creates a stable allylic carbocation
that could be attacked by the nucleophilic amino group. Hydration of the
double bond to form a secondary alcohol, oxidation to form the tertiary
alcohol, and oxidation to form the thiazole ring are required steps to
ultimately form fragment A. Another, more likely possibility is the
condensation of cysteine with a,dihydroxyisovalerate, an intermediate in
valine biosynthesis. Provided that cultured Lyngbya majuscula produces 1,
feeding studies can be proposed to distinguish between the various
biosynthetic pathways. Enrichment of carbon 13 subsequent to feeding
cultured Lyngbya majuscula labeled dimethylallyl diphosphate would
support the hypothesis that dimethylallyl diphosphate is included in the
biosynthesis. The second hypothesis would be supported by enrichment,
subsequent to feeding cultured Lyngbya majuscula labeled
a,dthydroxyisova1erate. The role of cysteine as a precursor could be probed
with labeled cysteine feeding studies. Cellular extracts may be more
appropriate to perform biosynthesis studies on, presuming the cellular uptakeA
C
OH
25
I3
HO'J%
Figure 2.6 The fragments generated from a theoretical hydrolysis of
hectochiorin. Two equivalents of fragment A would be generated. Fragment
A contains a thiazole ring and a vicinal diol. Fragment B is an a -methyl-3-
hydroxy--dichloro fatty acid. Fragment C is acetic acid.of charged species, such as dimethylallyl diphosphate, and
a,fdihydroxyisova1erate is poor.
Fragment B is likely the product of polyketide anabolism. A likely path
of biosynthesis is an acetyl-CoA starter unit condensed with three units of
malonyl-CoA. The a-methyl moiety could result if the penultimate module
lacks dehydration function, and instead oxidizes the polyketide to an enol,
followed by stereospecific methylation, which results in an a-methyl-n-
hydroxyl as found in 1. An alternate possibility of an acetyl-CoA starter unit,
condensed with two malonyl-CoA units, then finally a methylmalonyl-CoA
unit, also explains the presence of the a-methyl moiety. This hypothesis
requires the stereospecific loading and incorporation of methylmalonyl.
Fragment C is very likely to be the result of a simple acetylation. Labeled
acetate would probe this possibility.
SUMMARY
In this chapter, the absolute configuration of hectochiorin, as
determined by x-ray crystallography, has been reported as 6S, 7S, 105, 31S, and
its possible biogenesis has been discussed. Marine natural products are a
source of novel chemical backbones and provide skeletons for combinatorial
synthesis, therapeutic agents, and insight into new biosynthesis possibilities.
Lyngbya majusculacontinues to yield secondary metabolites that are
potentially valuable as therapeutic agents or have industrial applications.27
Chapter 3 Crystallization of TAR
INTRODUCTION
A crystal structure can give a wealth of information for structure-
assisted drug design. Obtaining diffraction quality crystals is the first step in
the process. Reported in this chapter are the results of attempts to crystallize
an RNA molecule of significant biological importance, the trans-acting
response element of HIV, to advance structure-assisted drug design efforts.
Efficient transcription of the HIV genome requires interaction between
the viral trans-activating transcription protein (Tat) and the trans-activating
response element (TAR). TAR is the 59 nt leader sequence found at the 5'-
end of every viral mRNA transcript. The sequence folds into a hairpin
conformation, with a two to three base bulge, that is specifically recognized by
Tat. The bulged hairpin structure is critical for the Tat-TAR interaction. This
protein-RNA interaction results in increased RNA polymerase processivity.
This interplay does not have an analogous host interaction, which makes it
an attractive target for the development of anti-viral agents (17).
After incorporation into the host cell, the viral RNA genome is
transcribed into DNA by viral reverse transcriptase (RT). The viral genome
is then inserted into the host's DNA by viral integrase (IN). After a latency
period the viral genome is replicated by the host transcription machinery, and
as the viral messages are transcribed, the Tat-TAR interaction assures
processivity and complete transcript production. HIV protease (PR) thenenables packaging of the viral particle by modification of capsid proteins (17).
These four viral activities, RT, IN, Tat, and PR, are potential targets for drug
design. Currently, the arsenal against HIV includes drugs that inhibit RT and
PR. The sloppy copying of RT introduces mutations that result in resistant
variants. Hence, the rapid mutation rate limits the long term potency of any
one agent. Therefore, novel agents and strategies are in constant demand as
resistant viruses are selected.
Tat is an 86 amino acid viral protein with five domains. The 48
residues at the N-terminus form a transcriptional cofactor binding domain.
An arginine rich domain motif (ARM), from residue 49 to 58, is required for
recognition of TAR. The other domains include a core domain and a cysteine
rich region. The cysteine rich domain can complicate biochemical studies
with Tat by forming non-native disulfide bridged complexes (18).
Polyarginine polypeptides bind specifically and efficiently to TAR. However,
polylysine polypeptides do not bind specifically and the binding constant is
reduced by a factor of 10 relative to polyarginine. Arginine 52 and 53 of the
ARM are the principal residues in the Tat-TAR interaction (19). A single
arginine amino acid binds specifically, and will effectively compete with the
entire Tat protein (20, 21). Arginine and argininamide are common
substitutes for Tat in structural studies. The guanidinium group of the
arginine residue forms an arginine fork, a network of hydrogen bonds, with
the G26C39 base pair in TAR (19).29
The viral genome is laid out in tandem repeats. Without Tat present,
the transcription complex of host machinery is formed, but has low
processivity. The low processivity creates abortive complexes that can not
lead to a new generation of infectious viral particles. In contrast, the Tat-TAR
complex is processive and generates complete viral messages. The Tat-TAR
complex alone can maintain the phosphorylation of the C-terminal domain
of RNA polymerase II (22). Accessory proteins to Tat also increase
processivity of the transcription machinery. After Tat binds to TAR, cyclin T
associates with Tat and the TAR loop region. The associated kinase, CDK 9,
increases processivity by hyper-phosphorylating the RNA polymerase
machinery (23, 24, 25).
The native TAR sequence is 59 nt long, however, the consensus
sequence required for activity is a truncated component of this. A uracil
containing bulge, flanked by a stem and a stem loop, is conserved in the
consensus sequence (26). Figure 3.1 depicts the secondary structure of the
wild type and consensus sequences. The conserved uracil in the bulge is
protected in biochemical assays, which suggests that it may be tucked into the
major groove, perhaps forming a base triplet between U23 and the A27.U38
base pair (20, 27, 28).
The formation of the U23.(A27.U38) base triplet is an important feature
to the binding of Tat. Mutation studies show that the loss of the base pair
portion (A or U) of the trio deletes activity. Additionally, a mutation of the30
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Figure 3.1 The wild-type sequence of HIV TAR and the consensus sequence
of TAR. Panel A is the secondary structure of the 59 nucleotide long TAR
sequence. The major features of the planar structure are a stem, bulge, and
stem ioop. Panel B shows the conserved structure required for Tat
recognition. The required residues are in bold, and elements with a moderate
effect on binding are italicized. The G26.C39 base pair may be required to form
the arginine fork interaction with Tat. U23 in the bulge may interact with
base pair A27.U38 to form a triplet (20, 27). supporting the requirement of
the base triplet (20). The base triplet may stabilize a widening of the major
groove of the helix that facilitates binding of Tat (29, 30).31
bulge residue destroys activity. However, a triple mutation that restores a
base pair (G.C) and places a C in the bulge is recognized and bound by Tat,
The structures of TAR unbound and bound to Tat are critical to
understanding this important step in viral replication. Previously reported
structures of TAR present conflicting results and leave unanswered questions
as to what are the detailed three dimensional structures of the bound and
unbound forms of TAR.
Puglisiet al.(1992) used NMR to investigate the structure of TAR.
Their construct was a bulged, stem loop. The model of TAR bound to
arginine resulting from their data suggested that arginine forms an arginine
fork with the G26C39 base pair. Their model also shows that U23 is
positioned in the major groove in such a way as to form a base triplet with
the A27U38 base pair (31). Aboul-elaet al. (1995)also used NMR to
investigate the TAR hairpin structure. With a larger number of data to
restrain their model building, which should lead to a more accurate model,
they proposed a different structure. Similar to Puglisiet al.,their model
contains an arginine fork with G26C39 and U23 is tucked into the major
groove of the helix. However, the distance between U23 and its potential
partners is too great to form a base triplet (32). This leaves us with two
conflicting perspectives of the TAR structure, both models are from NMR, a
technique that relies on close contacts for developing distance constraints.
A third model has been presented by Ippolito and Steitz (1998) who
solved the crystal structure of a bulged duplex TAR construct in the presence32
of Ca2. Their data gives yet another model for TAR. This construct lacked
the loop portion of the consensus sequence. One advantage of a crystal
structure is that the solvent environment can be defined. In this model we
see that U23 is displaced out of the major groove, nowhere near the A27U38
base pair. The bulge conformation was stabilized by calcium ions (33). The
position of U23 in this model is inconsistent with biochemical evidence and
both NMR models, which suggest U23 is protected in the major groove. Low
concentrations of magnesium have been shown to change the conformation
of TAR, thus more information is required to determine if this crystal
structure is a relevant unbound conformation (34).
There are three structures of TAR, and each tells a different tale. There
is evidence that a conformational change occurs upon binding arginine, so
each may be a relevant piece of a dynamic process. Long and Crothers suggest
the unbound conformation of TAR is bent at the bulge, and upon binding,
the stems stack co-axially (27, 28). Clearly, there is a need for detailed crystal
structures of arginine or argininamide bound TAR, and the unbound form of
TAR. The structures will support or challenge the presence of a base triplet
and the conformation change that may occur upon ligand binding.
Detailed models are key to structure assisted drug design. A crystal
structure can show details of the surrounding solvent, which can give
insights into drug design and improvement. All available structures should
be considered in designing cognate contacts for the unbound conformation
and contacts that will increase stabilization of the bound form.33
The first step in solving a crystal structure involves determining the
conditions that generate diffraction quality crystals of a biologically relevant
construct. Various salts, buffers, and precipitants can be screened to find the
optimal conditions that foster crystal growth. Large polyelectrolytescan be
problematic; nucleic acids are, more or less, a uniform landscape of repelling
negative charges that can shift slightly and distort a crystal lattice. This
distortion reduces the quality of the diffraction data and hence, the quality of
the model fit to the data.
To improve lattice contacts in nucleic acid crystals, Ferre'-D'Amare' et
al., incorporated non-native structure motifs that lead to the crystallization of
several large RNA molecules. Originally observed as a lattice contact, the
GNRA tetraloop (TL), and GNRA (where G is guanine, N is any nucleotide, R
is a purine, and A is Adenosine) tetraloop receptor (TLR), are observed in the
P4-P6 domain of the group I intron ribozyme and the hammerhead ribozyme.
Unbound, the adenosine bases in the TLR are stable in an adenosine zipper
motif. The bound conformation of the IL is stabilized by a base quartet, base
pairing, and an adenosine platform (35). A TL and TLR were successfully
employed as crystallization modules, an inter-domain stabilizing interaction,
for the crystallization of the group II intron 5-6 domains, and the hepatitis
delta virus ribozyme (36, 37).
With this strategy in mind, the sequences in Figure 3.2 were developed
to utilize this interaction. The binding of one TL into a TLR on another
molecule should facilitate crystallization by providing a defined interaction.Tetraloop
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Figure 3.2 TAR sequences used in this study. The sequence and proposed
secondary structure of TAR-a and derivatives. These variants of TAR-a differ
in phase and spacing. The conserved bases are in bold, and bases with a
moderate effect on Tat binding are italicized. The tetraloop and tetraloop
receptor regions are marked with boxes.35
As shown by the wild type and consensus sequences in Figure 3.1 the binding
of Tat to TAR is unaffected by residue substitution in the ioop region of TAR.
Also, the stem region distal to the ioop allows broad substitution. The
sequence and positioning of the TL and TLR in TAR constructs at the loop
and on the stem leaves the consensus sequence pristine. The polarity and
spacing of the TLRs differs between the designed sequences to provide
various contact orientations between the modules. The TL TLR constructs
should facilitate crystallization and ultimately provide biologically relevant
structures. Indeed, the constructs did prove to be crystallogenic in a variety of
conditions.
MATERIALS AND METHODS
TAR sequences were synthesized on an Applied Biosystems Inc. DNA
synthesizer. NAP-lU columns of G-25 Sephadex, DNA grade, were obtained
from Amersham Pharmacia. Reagent grade concentrated ammonium
hydroxide was obtained from J.T. Baker. Absolute ethanol, 1 M
tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF), 99.8% Tris-
HC1 and 99.8%+ grade ammonium acetate were obtained from Aldrich. 3 cc
syringes and multiwell tissue culture plates were obtained from Becton
Dickinson & Co. HPLC grade acetonitrile, Eppendorf tubes, sterile 50 mL and
15 mL conical tubes were obtained from Fisher Scientific. Semi-preparative
(10 mm x 250 mm) C-18 Absorbosphere HPLC column was obtained from
Alitech. 0.45 pm Nylaflow 47 mm nylon membrane filters obtained from36
Gelman, and 0.45 tim Durapore membrane filters 47 mm were obtained from
Millipore. pH determinations were performed on a Corning 120 pH meter,
that was calibrated prior to measurement. Natrix screen solutions, and
silanized glass cover slips were purchased from Hampton Research. The
HPLC system was composed of a Hewlett-Packard Ti 1050 pump and Hewlett-
Packard 1040A UV detector.loxtriethylammonium acetate (TEAA) stock
aqueous solvent was made up using 700 mL autoclaved distilled deionized
(dd) water, 75.25 mL concentrated acetic acid (Sigma), and 139.4 mL ACS grade
triethylamine (Sigma) titrated with acetic acid to pH 6.5. RNA concentrations
were determined using a Hewlett-Packard 8452A spectrophotometer and
extinction coefficients in Table 3.1.
Removal of sequence from synthesis cartridge and deprotectionofamines
2 mL of 3: 1 ammonium hydroxide : ethanol solution is loaded into a 3 cc
syringe, purged to remove trapped air and then attached to one end of the
synthesis cartridge. A second 3 cc syringe is placed on the other end with 0.5
mL of head space. The syringes are alternately pushed/pulled 5 times slowly
to drive the solution through the cartridge resin. The agitation is repeated
after 15 mm. then every 30 mm. for 3 hours. Between agitation steps the
solution is positioned to bathe the cartridge resin. Finally, the solution is
expelled into glass vials, sealed and heated 12 hours at 55° C.Table 3.1 Molecular weights and extinction coefficients at 260 nm used for
TAR constructs. This table lists the extinction coefficients of the TAR
constructs used in this study. The extinction coefficients,molar1cm1,were
calculated at 260 nm using neighboring interactions. Masses were calculated
with ammonium counter ion.
TAR 8260 nm(M1cm') Molecular Weight (g/mol)
construct
TAR-a 323,900 10,994.8
TAR-p5 341,000 12,273.2
TAR-m3 308,600 10,904.438
Deprotection of 2' hydroxyls
The material is transferred to Eppendorf tubes using two 100 L washes
to rinse vials and assist transfer. The sample is then lyophilized. The dry
powder is dissolved in 300 p.L of 1 M TBAF in THF and gently agitated 16
hours.
NAP-lO Column Purification
NAP-b columns are prepared by draining until mobile phase reached
the G-25 resin bed. TBAF reaction products of like sequences are combined
and transferred to the column using 200 jit dd water rinses (total volume 1
mL). Material is eluted by loading 800 p.L dd water, followed by up to six 500
iL aliquots of dd water. The fractions are then ethanol precipitated by the
addition of 50 tL 8 M ammonium acetate, 1100 i.L absolute ethanol, chilling
at -80°C for 25 mm., then spinning 14,000 rpm, 25 mm. at 4°C. Fractions that
contained a pellet are combined and ethanol precipitated again.
HPLC purification
Table 3.2 illustrates the gradient used in the separation. The (A)
solvent is 0.1 M TEAA pH 6.5 and the (B) solvent is acetonitrile. The
solvents are filtered with 0.45xm and degassed with helium approximately 15
mm. prior to use. Samples are centrifuged prior to injection onto the HPLC39
Table 3.2 HPLC gradient for RNA purification. RNA sequences are purified
by C-18 high performance liquid chromatography using 0.1 M
Triethylammonium acetate (pH 6.5), (A), and HPLC grade acetonitrile, (B), in
the following gradient. Solutions were filtered with 0.45 jim membrane
filters and degassed with helium prior to use. The flow rate was 2 mL/ mm.
for the entire gradient.
Time (mm.) Mobile Phase (%B)
0 0
5 0
10 20
20 30
25 30
27 50
30 50
35 0column. The flow rate is 2 mL/min. Elution is monitored by UV. Fractions
are dried down, combined by sequence using 100 mM Tris-HC1 pH 7.5, then
concentrated by ethanol precipitation.
Detritylation
Sequences are detritylated in the following manner: to 50 p.L of sample
in 100 mM Tris-HC1 pH 7.5 an equal volume of glacial acetic acid is added.
The reaction is allowed to run for 30 mm. at room temperature. The reaction
is quenched by the addition of 10 pL 1 M Tris-HC1 pH 7.5. 10 p.L 8 M
ammonium acetate, 80 jit dd water and 600 jiL absolute ethanol are then
added for precipitation.
Hanging drop crystallization setups
The concentration of each purified detritylated sequence is determined
spectrophotometrically using the extinction coefficients in Table 3.1. The
sample is then concentrated with an ethanol precipitation and brought up to
a concentration of 4 mg/ mL. Samples are centrifuged prior to setup. Equal
volumes of each sequence and Natrix screen solution, plus or minus
argmninamide, are dispensed onto a silanized glass cover slip as per Table 3.3.
The cover slip is then inverted and placed over a 750 jiL reservoir with a
greased lip.41
Table 3.3. Crystallization conditions for hanging drop setups of TAR
constructs. Crystals formed in 1 to 4 weeks. Precipitant concentrations are
reported in percent volume/volume. Final concentrations are reported and
the total drop volume was approximately 20 p.L. Both 2-methyl-2,4-
pentanediol (MPD), and polyethylene glycol (PEG) were used as precipitant
this study. Argininamide (ArgNH2) was used as a Tat analogue.
Sample, Buffer Salts, Other Precipitant
Concentration (% (v/v))
TAR-m3, 22 mM Tris-HC1
(pH 7.5)
1.78 mg/mL
TAR-p5, 25 mM
NaCacadylate
2mg/mL (pH6.5)
TAR-a, 22 mM Tris-HC1
(pH 7.5)
1.78 mg/mL
TAR-a, 25 mM Tris-HC1
(pH 7.5)
2mg/mL
1 mM ArgNH2, 10 % MPD
22 mM NH4OAc,
4.4 mMMgC12,
4.4 % MPD
40 mM MgOAc2,15% PEG 400
7.5 % PEG 400
1 mMArgNH2,
22 mM NH4OAc,
4.4 mMMgC12,
4.4 % MPD
1 mMArgNH2,
22 mM NH4OAc,
4.4 mMMgCl2,
4.4 % MPD
10%MPD
10%MPD42
Freezing Conditions
Crystals are mounted in a thin nylon ioop, andpassed through
cryoprotectant quickly to exchange themother liquor. The cryoprotectant is
composed of a solution of salts and buffer at aconcentration equal to initial
concentration crystallization conditions, plusadditional 2-methyl-2,4-
pentanediol to a final of 20% (v/v). The crystal issubmersed in liquid
nitrOgen and transferred to the goniometer with cryotongs.Data are collected
at -180°C using a Rigaku RU-300H rotating anode x-ray generatorand an
RAXIS IV image plate detector.
RESULTS AND DISCUSSION
The modular TL-TLR approach proved to be successful, providing a
handful of conditions that give rise to crystal growth (Table 3.3). Crystallizing
conditions have proven reproducible for TAR-a sequences (Figure 3.3). Panel
A of Figure 3.3 shows a colorless crystal, approximately 0.1 x 0.1 x 0.1mm3,
from a well containing TAR-a and argininamide. Panels B and C of Figure 3.3
present crystals from wells containing the TAR-a sequence,both crystals are
colorless, and approximately 0.2 x 0.2 x 0.2mm3. Second generation
sequences, TAR-p5 and TAR-m3, provedcrystallogenic as well. Panels D and
E of Figure 3.3, show crystals grown from wells containing TAR-m3 with
argininamide, and TAR-p5, respectively.4
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Figure 3.3 Crystals grown from wells containing TAR sequences. Panel A
shows a colorless, 0.1 x 0.1 x 0.1 mm3, crystal grown from a well containing
TAR-a and argininamide. Panels B and C are pictures of colorless 0.2 x 0.2 x
0.2mm3crystals grown from wells contain TAR-a. Panel D shows two
football shaped, 0.2 x 0.1 x 0.15 mm3, crystals grown from wells containing
TAR-m3 and argininamide. Panel E shows a shower of cubic crystals grown
from a well containing TAR-pS.The crystals were checked for their diffraction quality, see Figure 3.4.
The TAR-a crystal in Figure 3.3, panel A, was screened, and diffracted out to
about 12A(Figure 3.4, Panel A). The TAR-m3 crystal shown in Panel D of
Figure 3.3, diffracted out to approximately 15A(Figure 3.4, Panel B). The
resolution of this data is poor, and cannot be used to solve the structure.
Unfortunately, reliable unit cell dimensions and space group could not
determined from the data collected.
One common feature of all the reported crytallization conditions is
magnesium, a divalent cation. This is not unexpected, as cations are often a
requirement for the folding of native RNA structures, such as ribozymes.
The freezing conditions for storage and protection from degradation in the x-
ray beam have been determined. This will facilitate transportation and data
collection at synchrotron sources. A synchrotron beam source may be a
requirement for collection of higher quality data from these crystals.
JkW.d
Conditions have been determined that produce crystals of a biologically
relevant sequence of TAR. Crystals of TAR and TAR bound to argininamide
have been generated. Furthermore, crystallization conditions may be refined
to produce larger and higher quality crystals. Simplification of the phase
problem utilizing MAD may be achieved with brominated uridine derivative
sequences of TAR. A quality crystal that diffracts to high resolution can be
used to refine an accurate models of TAR for drug design purposes.Figure 3.4 Diffraction patterns from TAR crystals. Panel A is a diffraction
pattern collected on a crystal grown from TAR-a and argininamide.
Reflections were observed as far as 12A.Panel B is a diffraction pattern
collected on a crystal grown from TAR-m3 and argininamide. Reflections
only out to - 15Awere observed in this data.rir
Chapter 4 Conclusion
The field of structure-assisted drug design continues to mature. As the
number of receptor and ligand structures increases, the ability to tailor
molecules for a specific purpose from structural information alone becomes
more tangible. The further investigation of hectochiorin, and possible
development into a role in industry, or as a therapeutic agent can begin.
Determination of the absolute configuration is an early step in its
development. More biochemical information, such as the specific receptors it
antagonizes or agonizes, is required to complete further steps towards
maturation. The molecule can be made available for bench-top and
computational screens. As novel assays evolve and new applications are
discovered, the richness of structure libraries will be fully appreciated. Aside
from biological activity, it is worthwhile to survey the scope of chemical
compounds produced by secondary metabolite rich organisms such as
Lyngbya majuscula.Understanding the complete range of chemistry
available to the organism may lead to the production of novel products
through genetic manipulation.
We have made steps towards determining the three-dimensional
structure of TAR. At least two different rational drug design approaches have
begun development and could be assisted by an accurate model of TAR. A
split and mix technique has identified a peptoid analogue of Tat as a potent
inhibitor that blocks TAR.Tat formation at nanomolar concentrations (38).
Furthermore, aminoglycosides with arginine analogue substituents have47
been created that bind specifically to TAR (39). Computer modeling of these
Tat analogue compounds with TAR may lead to improvements in both of
classes of drugs.
Both the determination of the absolute structure of hectochiorin, and
results from TAR crystallization attempts, demonstrate structure-assisted
drug design is taking strides toward maturation.BIBLIOGRAPHY
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